TABLE 1.
Phase 2 and 3 clinical trials for eribulin in STS.
| Author | Study type | ECOG Performance Status | Soft tissue sarcoma subtype | Number of patients receiving eribulin | Median overall survival (months) | Median progression free survival (months) |
|---|---|---|---|---|---|---|
| Schöffski et al. (2016) | Randomised phase 3 trial versus dacarbazine | 0 (49%) | LPS and LMS | 228 | 15.6 | 2.6 |
| 1 (50%) | ||||||
| 2 (1%) | ||||||
| Schöffski et al. (2011) | Non-randomised, single arm phase 2 trial | 0 (64%) | LPS | 32 | Not reported | 2.6 |
| 1 (36%) | LMS | 38 | Not reported | 2.9 | ||
| Synovial | 19 | Not reported | 2.6 | |||
| Other sarcoma | 26 | Not reported | 2.1 | |||
| Kawai et al. (2017) | Non-randomised, single arm phase 2 trial | 0 (53%) | LPS and LMS | 35 | 17.0 | 5.5 |
| 1 (47%) | Other sarcoma | 16 | 7.6 | 2.0 |